-
23andMe (ME) Initiates Voluntary Chapter 11 Process
-
23andMe (ME) Launches New Homocysteine Genetic Report and Accompanying Lab Test
-
23andMe (ME) Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
-
Increasing unusual option volume: SNDX ALGM VNET RC HSBC ME ODFL DV LXRX EU BPMC
-
23andMe Holding Co. (ME) Launches New Genetic Report on Osteoporosis
-
23andMe Holding Co. (ME) Reports Q3 Loss of $1.02
-
23andMe Holding Co. (ME) to explore strategic alternatives, including possible sale
-
23andMe Holding Co. (ME) Halted, News Pending
-
23andMe (ME) quietly exploring a possible sale of its telehealth business, Lemonaid - Business Insider
-
23andMe (ME) Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
-
23andMe (ME) and Mirador Therapeutics Enter Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
-
23andMe Holding Co. (ME) Misses Q2 EPS by 216c
-
23andMe (ME) Regains Nasdaq Compliance
-
23andMe Holding Co. (ME) Appoints Andre Fernandez, Jim Frankola, and Mark Jensen to its Board
-
23andMe Holding Co. (ME) Completes 1:20 Reverse Share Split
-
23andMe Holding (ME) Announces 1:20 Reverse Share Split
-
23andMe Holding (ME) Appoints Mathew Knowles as Brand Ambassador
-
23andMe Holding Co. (ME) Launches New Genetic Report on Likelihood of Frequent Emotional Eating
-
23andMe Holding (ME) no longer in compliance with Nasdaq listing rules
-
23andMe Holding (ME) Announces Resignation of Independent Directors from Board
-
23andMe Holding Co. (ME) Reports Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
-
Citi Reiterates Neutral Rating on 23andMe Holding (ME)
-
23andMe (ME) CEO Wojcicki Open To Considering Takeover Proposals - Bloomberg
-
23andMe (ME): Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership Program
-
23andMe Holding Co. (ME) Tops Q1 EPS by 8c
-
23andMe Holding Co. (ME) Special Committee responds to CEO’s take-private proposal
-
23andMe Holding Co. (ME) Announces CEO’s $0.40/sh Take-Private Proposal
-
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
-
ICO to investigate 23andMe data breach with Canadian counterpart

